Abeona Therapeutics (ABEO) Income from Continuing Operations (2011 - 2026)
Abeona Therapeutics' (ABEO) quarterly Income from Continuing Operations came in at 17075000.0 in Q1 2026, down 41.95% year-on-year from 29413600.89 in Q1 2025, and up 51.67% quarter-over-quarter from 35330000.0 in Q4 2025.
Abeona Therapeutics (ABEO) Income from Continuing Operations (2011 - 2026) Analysis & Trends
Abeona Therapeutics' Income from Continuing Operations history runs 16 years deep, the most recent figure standing at 17075000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 41.95% year-over-year to 17075000.0 in Q1 2026; TTM through Mar 2026 was 66779000.0, a 253.49% increase from a year earlier, with the FY2025 full-year figure at 56313000.0, up 189.31% from the prior year.
- Income from Continuing Operations advanced to 17075000.0 in Q1 2026 per ABEO's latest filing, from 35330000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 124345000.0 in Q2 2025 and bottomed at 35330000.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 13114000.0 (2022), against an average of 7428941.18.
- Biggest YoY gain for Income from Continuing Operations was 1578.98% in 2025; the steepest drop was 310.15% in 2025.
- Year by year, Income from Continuing Operations stood at 13114000.0 in 2022, then declined by 1.56% to 13318000.0 in 2023, then soared by 35.32% to 8614000.0 in 2024, then slumped by 310.15% to 35330000.0 in 2025, then surged by 51.67% to 17075000.0 in 2026.
- Per Business Quant, the three latest ABEO Income from Continuing Operations figures stand at 17075000.0 (Q1 2026), 35330000.0 (Q4 2025), and 5161000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Abeona Therapeutics | 107.85 Mn | -60.42 Mn | 6.02 Mn | -17.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -17.08 Mn |
| Dec 31, 2025 | -35.33 Mn |
| Sep 30, 2025 | -5.16 Mn |
| Jun 30, 2025 | 124.35 Mn |
| Mar 31, 2025 | -12.03 Mn |
| Dec 31, 2024 | -8.61 Mn |
| Sep 30, 2024 | -30.27 Mn |
| Jun 30, 2024 | 7.41 Mn |
| Mar 31, 2024 | -16.33 Mn |
| Dec 31, 2023 | -13.32 Mn |
| Sep 30, 2023 | -12.70 Mn |
| Jun 30, 2023 | -11.35 Mn |
| Mar 31, 2023 | -20.99 Mn |
| Dec 31, 2022 | -13.11 Mn |
| Sep 30, 2022 | -11.01 Mn |
| Jun 30, 2022 | -18.66 Mn |
| Mar 31, 2022 | -32.10 Mn |
| Dec 31, 2021 | -43.45 Mn |
| Sep 30, 2021 | -15.79 Mn |
| Jun 30, 2021 | -15.21 Mn |